[Frontiers in Bioscience E3, 1265-1272, June 1, 2011]

MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia

Lili Zeng1,2, Jianrong Liu1, Yongting Wang2, Ling Wang1, Suiqing Weng1, Yaohui Tang2, Chaobo Zheng1, Qi Cheng1, Shengdi Chen1, Guo-Yuan Yang1,2

1Department of Neurology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China, 2Neuroscience and Neuroengineering Center, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai 200030, China

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Materials and methods
3.1. Study subjects
3.2. Mouse model of permanent middle cerebral artery occlusion (pMCAO)
3.3. Blood sample collection
3.4. Brain tissue sample collection
3.5. RNA extractions
3.6. Reverse transcriptions (RT)
3.7. Real time quantitative PCR
3.8. Statistical data analysis
4. Results
4.1. Clinical Characteristics
4.2. Changes of blood miR-210 in acute ischemic stroke patients
4.3. The relationship between blood miR-210 and the outcome of ischemic stroke
4.4. The relationship between blood miR-210 and ischemic stroke subtype
4.5. The relationship between blood miR-210 and brain miR-210 in pMCAO mouse
5. Discussion
6. Acknowledgment
7. References

1. ABSTRACT

MicroRNA-210 (miR-210), a master and pleiotropic hypoxia-microRNA, plays multiple roles in brain ischemia. However, miR-210 expression and its function in humans have not been explored. The aim of our study is to evaluate the correlation of blood miR-210 with clinical findings in acute ischemic stroke. Blood samples were obtained from stroke patients (n=112) and healthy controls (n= 60). MiR-210 was measured at within 3, 7 and 14 days after stroke using a quantitative PCR technique. Stroke severity and clinical outcome were evaluated by NIHSS and modified Rankin Score. Both blood and brain miR-210 in ischemic mice was examined and the correlation was investigated. Compared to healthy controls, blood miRNA-210 was significantly decreased in stroke patients (0.93 vs. 1.36; P=0.001), especially at 7 days (0.56 vs. 1.36; P=0.001) and 14 days of stroke onset (0.50 vs. 1.36; P=0.001). The cut off point of miR-210 in diagnosis was 0.505 with 88.3% sensitivity. MiR-210 level in stroke patients with good outcome was significantly higher than patients with poor outcome (1.2 vs. 0.44; P=0.012). The correlation between blood and brain miR-210 in ischemic mice was positive (R2=0.57, P=0.001). Blood miR-210 is a novel sensitive biomarker for clinical diagnosis and prognosis in acute cerebral ischemia.